Hepatoid adenocarcinoma of the lung and the review of the literature

2020 ◽  
Vol 26 (6) ◽  
pp. 1505-1510
Author(s):  
Onder Tonyali ◽  
Onur Gonullu ◽  
Mehmet Akif Ozturk ◽  
Aysun Kosif ◽  
Ozlenen Gonca Civi
Keyword(s):  
Concurrent Chemoradiotherapy ◽  
Mediastinal Lymph Node ◽  
Alpha Fetoprotein ◽  
Disease Stage ◽  
Hepatoid Adenocarcinoma ◽  
Rare Type ◽  
Adenocarcinoma Of The Lung ◽  
Female Smoker ◽  
Diagnostic Biopsy ◽  
Serum Alpha Fetoprotein

Introduction Hepatoid adenocarcinoma of the lung is an extremely rare type of the non-small cell lung cancer. Treatment principles and prognosis are similar to that of lung adenocarcinoma. Case report A 62-year-old female smoker presented with a huge mass in the left upper lobe. After diagnostic biopsy, she underwent left pneumonectomy and mediastinal lymph node dissection. A diagnosis of stage T4N1M0 hepatoid adenocarcinoma of the lung with positive surgical margins was made. Management and outcome After the operation, the level of serum alpha fetoprotein was 9010 ng/ml (N: <10). The level of serum alpha fetoprotein was decreased with concurrent chemoradiotherapy and chemotherapy. Disease progression was detected at 11 months after diagnosis. No response was obtained to other therapies. The patient died at 14 months from the time of diagnosis. Discussion Usually, patients with hepatoid adenocarcinoma of the lung are male smokers. Hepatoid adenocarcinoma tends to settle in the upper lobes of the lung. The most important prognostic factor of the hepatoid adenocarcinoma of the lung is the disease stage at the diagnosis and patients with metastatic disease have poor survival.

scholarly journals Primary Hepatoid Adenocarcinoma of the Lung

2016 ◽  
Vol 50 (2) ◽  
pp. 103-106 ◽  
Author(s):  
Uma Devaraj ◽  
Gnanapriya Vellaisamy ◽  
Julian Crasta
Keyword(s):  
Needle Aspiration ◽  
Hepatoid Adenocarcinoma ◽  
Male Smoker ◽  
Rare Type ◽  
Adenocarcinoma Of The Lung ◽  
Thyroid Transcription Factor ◽  
Atypical Cells ◽  
Serum Alpha Fetoprotein ◽  
Clear Cytoplasm ◽  
Needle Aspiration Cytology

ABSTRACT Hepatoid adenocarcinoma lung (HAL) is an extremely rare type of extrahepatic adenocarcinoma with morphological similarity to hepatocellular carcinoma. We report a case of 59 years male smoker who presented with anorexia, weight loss and cough. Chest X-ray revealed a homogenous opacity in the left upper and mid zone. Computed tomography (CT) chest showed a left upper lobe mass with enlarged hilar lymph nodes. Serum alpha fetoprotein (AFP) was normal. Guided fine needle aspiration cytology (FNAC) of the mass revealed a few atypical cells. Endobronchial biopsy showed sheets of polygonal cells with coarsely clumped chromatin, eosinophilic nucleoli and abundant eosinophilic to clear cytoplasm. The neoplastic cells were positive for hepatocyte-1, Carcinogenic embryonic antigen (CEA), Cytokeratin 7 (CK-7) and cytoplasmic positivity for thyroid transcription factor (TTF-1). After 3 months, the tumor had grown significantly. Due to its aggressive behavior, early and accurate diagnosis is necessary. How to cite this article Vellaisamy G, Rout P, Crasta J, Devaraj U. Primary Hepatoid Adenocarcinoma of the Lung. J Postgrad Med Edu Res 2016;50(2):103-106.

Familial synchronous bilateral teratoid Wilms tumor with elevated alpha-fetoprotein level

2012 ◽  
Vol 98 (6) ◽  
pp. e179-e182 ◽  
Author(s):  
Arzu Okur ◽  
Faruk Guclu Pinarli ◽  
Ceyda Karadeniz ◽  
Aylar Poyraz ◽  
Kibriya Fidan ◽  
...  
Keyword(s):  
Tumor Volume ◽  
Age Of Onset ◽  
Wilms Tumor ◽  
Alpha Fetoprotein ◽  
Rare Entity ◽  
Rare Type ◽  
Specific Tumor ◽  
Serum Alpha Fetoprotein ◽  
First Time ◽  
Specific Tumor Marker

Familial Wilms tumor is a rare entity that accounts for only 1–2% of all Wilms tumor cases, with an earlier age of onset and an increased frequency of bilateral tumors. Teratoid Wilms tumor is a variant of nephroblastoma with a predominance of heterologous tissues comprising more than 50% of the tumor volume. Wilms tumor does not usually secrete any specific tumor marker and all teratoid Wilms tumor cases previously reported were sporadic non-secreting neoplasms. Here we describe an infant with familial synchronous bilateral teratoid Wilms tumor whose serum alpha-fetoprotein level was elevated. To our knowledge, this extremely rare type of case is reported for the first time in the literature.

scholarly journals Hepatoid Adenocarcinoma of the Lung

2021 ◽  
Vol 20 ◽  
pp. 153303382110579
Author(s):  
Meihui Li ◽  
Ying Fan ◽  
Hongyang Lu
Keyword(s):  
Immunohistochemical Staining ◽  
Case Reports ◽  
Hepatoid Adenocarcinoma ◽  
Pathological Features ◽  
High Concentration ◽  
Statistical Research ◽  
Rare Type ◽  
Adenocarcinoma Of The Lung ◽  
Complete Surgical Resection ◽  
Clinical And Pathological Features

Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. HAL morphologically and pathologically exhibits hepatocellular carcinoma (HCC)-like characteristics, while its clinical features resemble pulmonary adenocarcinoma. High concentration of alpha-fetoprotein (AFP) is often detected in the serum of HAL patients with no hepatic occupying lesion. Patients with AFP-negative HAL survive a few months longer than those with positive AFP test. HAL is a rare type of carcinoma, so there is a lack of systematic and extensive statistical research. The treatment strategy for HAL is similar to common lung adenocarcinoma. Complete surgical resection and adjuvant chemotherapy are the current major treatments for HAL patients. There are also a few of case reports suggesting that HAL patients may benefit from immunotherapy and targeted therapy. This review focuses on the clinical and pathological features, immunohistochemical staining characteristics, treatment and prognosis of HAL.

scholarly journals A Resected Case of Alpha-fetoprotein-producing Hepatoid Adenocarcinoma of the Lung

Haigan ◽  
2003 ◽  
Vol 43 (1) ◽  
pp. 29-34 ◽  
Author(s):  
Kenji Iino ◽  
Yasuhiko Ohta ◽  
Masaya Tamura ◽  
Hideo Sato ◽  
Kazuyoshi Katayanagi ◽  
...  
Keyword(s):  
Alpha Fetoprotein ◽  
Hepatoid Adenocarcinoma ◽  
Adenocarcinoma Of The Lung ◽  
Resected Case

scholarly journals Carcinosarcoma of the stomach with alpha-fetoprotein-producing hepatoid adenocarcinoma: an unexpected combination of two rare subtypes of gastric cancer in one tumor

2021 ◽  
Vol 49 (8) ◽  
pp. 030006052110374
Author(s):  
Zhongqi Li ◽  
Quan Zhou ◽  
Jun Lu ◽  
Haibin Zhang ◽  
Lisong Teng
Keyword(s):  
English Literature ◽  
Elevated Serum ◽  
Subtotal Gastrectomy ◽  
Malignant Neoplasm ◽  
Alpha Fetoprotein ◽  
Hepatoid Adenocarcinoma ◽  
Rare Type ◽  
Uterine Tumors ◽  
Resected Tumor ◽  
Tumor Types

Carcinosarcoma is a rare malignant neoplasm comprising both epithelial and mesenchymal components. Hepatoid adenocarcinoma (HAC) is another rare type of cancer. To date, there are only four reported cases of concurrent carcinosarcomas with HAC across all tumor types, all of which were observed in uterine tumors. Here, we report an unusual case of gastric carcinosarcoma associated with alpha-fetoprotein (AFP)-producing HAC in a 76-year-old woman. Upon admission, the patient had an elevated serum AFP concentration (448 µg/L), a necrotic polypoid tumor of the central gastric cardia revealed by endoscopy, and no evidence of distant metastasis indicated by computed tomography (CT). Owing to malignancy indicated by biopsy, the patient underwent proximal subtotal gastrectomy. The resected tumor was composed of both an HAC component and a sarcoma component, microscopically. The sample was positive for AFP, hepatocyte paraffin (Hep-Par) 1, glypican-3, SALL4, CDX2, cytokeratin (CK) (pan), CK18, desmin, and vimentin staining immunohistochemically. In summary, the tumor was diagnosed as carcinosarcoma of the stomach with AFP-producing HAC. To our knowledge, this is the first report of gastric carcinosarcoma with AFP-producing HAC in the English literature describing gastric tumors.

scholarly journals Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 169-174
Author(s):  
Lei Lei ◽  
Liu Yang ◽  
Yang-yang Xu ◽  
Hua-fei Chen ◽  
Ping Zhan ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Features ◽  
Survival Benefit ◽  
Stage Iv ◽  
Primary Lesion ◽  
Hepatoid Adenocarcinoma ◽  
Seer Database ◽  
Primary Tumor Size ◽  
Adenocarcinoma Of The Lung ◽  
To Receive

Abstract Hepatoid adenocarcinoma of the lung (HAL) is a rare malignant tumor that is defined as a primary alpha-fetoprotein (AFP)-producing lung carcinoma. We aimed to identify prognostic factors associated with the survival of patients with HAL using data from the Surveillance, Epidemiology, and End Results (SEER) database. We collected data from patients diagnosed with HAL, adenocarcinoma (ADC), and squamous cell carcinoma (SCC) of the lung between 1975 and 2016 from the SEER database. The clinical features of patients with ADC and SCC of the lung were also analyzed. The clinical features of HALs were compared to ADCs and SCCs. A chi-square test was used to calculate the correlations between categorical variables, and a t test or Mann–Whitney U test was used for continuous variables. The Kaplan–Meier method and Cox regression analysis were used to identify the prognostic factors for the overall survival (OS) of HALs. Two-tailed p values < 0.05 were considered statistically significant. Sixty-five patients with HAL, 2,84,379 patients with ADC, and 1,86,494 with SCC were identified from the SEER database. Fewer males, advanced stages, and more chemotherapy-treated HALs were found. Compared to patients with SCC, patients with HAL were less likely to be male, more likely to be in an advanced stage, and more likely to receive chemotherapy (p < 0.05). The American Joint Committee on Cancer staging was the only prognostic factor for OS in patients with HAL, and stage IV was significantly different from other stages (hazard ratio = 0.045, 95% confidence interval: 0.005–0.398, p = 0.005). Males with HAL were more likely to receive radiotherapy compared to females with HAL (61.8 vs 31.5%, p = 0.034). Younger patients with HAL were more likely to receive chemotherapy (59.4 + 10.2 years vs 69 + 11.3 years, p = 0.001). The primary tumor size of HAL was associated with the location of the primary lesion (p = 0.012). No conventional antitumor therapies, including surgery, chemotherapy, and radiotherapy, were shown to have a significant survival benefit in patients with HAL (p > 0.05). This study showed that stage IV was the only prognostic factor for OS in HALs compared to other clinicopathologic factors. Conventional antitumor therapies failed to show survival benefit; thus, a more effective method by which to treat HAL is needed. Interestingly, the clinical features and the location of the primary lesion were shown to be associated with primary tumor size and treatment in patients with HAL, which have not been reported before.

Sign in / Sign up

Export Citation Format

Share Document